Yahoo Finance

ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder

Company to host conference call and live webcast today at 09:00 am EDT (15:00 pm CET) MADRID and CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY ...
Finanznachrichten

Oryzon Genomics, S.A.: ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients

PORTICO-2 designed to validate vafidemstat's efficacy in reducing aggression in BPD patients Primary endpoint: STAXI-2 Trait Anger (patient-reported) Key secondary endpoint: Overt Aggression ...
Morningstar

ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder

Agitation-Aggression in Borderline Personality Disorder (BPD) acknowledged as a possible therapeutic indication Oryzon may use STAXI-2 Trait anger as a primary efficacy endpoint for PORTICO-2 ...